diazoxide has been researched along with Parkinsonian Disorders in 2 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Moreover, iptakalim and diazoxide reduced the enzymatic activities and mRNA levels of inducible nitric oxide synthase elicited by chronic administration of rotenone." | 1.33 | Systematic administration of iptakalim, an ATP-sensitive potassium channel opener, prevents rotenone-induced motor and neurochemical alterations in rats. ( Ding, JH; Hu, G; Liu, SY; Liu, X; Long, Y; Sun, YH; Wang, F; Wang, H; Wu, J; Yang, Y; Yao, HH, 2005) |
| " Studies also found that iptakalim and diazoxide could reduce the enzymic activities and mRNA levels of inducible nitric oxide synthase elicited by chronic administration of rotenone." | 1.33 | Activation of mitochondrial ATP-sensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats. ( Ding, JH; Hu, G; Liu, SY; Liu, X; Long, Y; Sun, YH; Wang, F; Wang, H; Wu, J; Yang, Y; Yao, HH, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, Y | 2 |
| Liu, X | 2 |
| Long, Y | 2 |
| Wang, F | 2 |
| Ding, JH | 2 |
| Liu, SY | 2 |
| Sun, YH | 2 |
| Yao, HH | 2 |
| Wang, H | 2 |
| Wu, J | 2 |
| Hu, G | 2 |
2 other studies available for diazoxide and Parkinsonian Disorders
| Article | Year |
|---|---|
Systematic administration of iptakalim, an ATP-sensitive potassium channel opener, prevents rotenone-induced motor and neurochemical alterations in rats.
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Basal Ganglia; Brain; Brain Chem | 2005 |
Activation of mitochondrial ATP-sensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Catalepsy; Decanoic Acids; Diazoxide; Disease Models, | 2006 |